BridgeMD
New treatment option for CHD
Official title Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial
ClinicalTrials.gov ID: NCT07514611
What this study is testing
- What it's testing
- Coronary Heart Disease (CHD) is an ischemic heart disease caused by coronary atherosclerosis, and it is the leading cause of death from cardiovascular diseases worldwide. Weight loss in obese patients can significantly improve metabolic indicators such as dyslipidemia and insulin resistance; therefore, weight loss may become a target for improving the prognosis of obese patients with coronary heart disease.
- Time commitment: about 1 year
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Age range: 18-65 years old .
- History of coronary heart disease confirmed by coronary angiography or coronary CTA, showing ≥50% stenosis in at least one major coronary artery...
- BMI: Body Mass Index (BMI) ≥ 28 kg/m²
- Weight loss willingness: Has the intention to lose weight
- Smartphone proficiency: Able to use a smartphone.
You likely can't join if
- Unstable angina pectoris or acute myocardial infarction occurring within the previous month;
- Comorbid endocrine or neurological diseases, cancer, or a history of bariatric surgery that affect body weight; or long-term use of medications that...
- Comorbid diseases that affect exercise capacity, such as severe cardiopulmonary diseases or osteoarthritic conditions;
- Comorbid diseases that affect diet, such as severe mental disorders, bulimia or anorexia nervosa, or cognitive dysfunction;
- Significant liver or kidney dysfunction, defined as: glomerular filtration rate \< 60 ml/(min 1.73m²) or undergoing dialysis; alanine transaminase...
- Severe language, psychological, or physical disabilities that prevent participation in the protocol;
See the full eligibility criteria
- Age range: 18-65 years old .
- History of coronary heart disease confirmed by coronary angiography or coronary CTA, showing ≥50% stenosis in at least one major coronary artery (left main coronary artery, left anterior descending artery, left...
- BMI: Body Mass Index (BMI) ≥ 28 kg/m²
- Weight loss willingness: Has the intention to lose weight
- Smartphone proficiency: Able to use a smartphone.
- Daily living ability: Capable of performing basic activities of daily living independently.
- Informed consent: Voluntarily participates in the study, signs a written informed consent form, and is willing to cooperate with follow-up
- Unstable angina pectoris or acute myocardial infarction occurring within the previous month;
- Comorbid endocrine or neurological diseases, cancer, or a history of bariatric surgery that affect body weight; or long-term use of medications that impact body weight;
- Comorbid diseases that affect exercise capacity, such as severe cardiopulmonary diseases or osteoarthritic conditions;
- Comorbid diseases that affect diet, such as severe mental disorders, bulimia or anorexia nervosa, or cognitive dysfunction;
- Significant liver or kidney dysfunction, defined as: glomerular filtration rate \< 60 ml/(min 1.73m²) or undergoing dialysis; alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 3 times the upper limit of the...
- Severe language, psychological, or physical disabilities that prevent participation in the protocol;
- Pregnant or lactating women, or individuals of childbearing potential who are unwilling/unable to use effective contraceptive measures;
- Participation in other treatment clinical trials;
- Body weight change exceeding 5% within the past year;
- Patients with a habit of long-term high-intensity exercise(more than 2 sessions per week of high-intensity endurance training, or more than 3 sessions per week of moderate-intensity endurance training);
- Patients deemed unsuitable for participation in the study by the researchers.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 1 year per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.